Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

High burden of ESBL and carbapenemase-producing gram-negative bacteria in bloodstream infection patients at a tertiary care hospital in Addis Ababa, Ethiopia.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: San Francisco, CA : Public Library of Science
    • الموضوع:
    • نبذة مختصرة :
      Background: Bloodstream infection due to beta-lactamase and carbapenemase-producing gram-negative bacteria poses a substantial challenge to the effectiveness of antimicrobial treatments. Therefore, this study aimed to investigate the magnitude of beta-lactamase, carbapenemase-producing gram-negative bacteria, and associated risk factors of bloodstream infections in patients at a tertiary care hospital, in Addis Ababa, Ethiopia.
      Methods: An institutional-based cross-sectional study was conducted with convenience sampling techniques from September 2018 to March 2019. Blood cultures were analyzed from 1486 bloodstream infection suspected patients across all age groups. The blood sample was collected using two BacT/ALERT blood culture bottles for each patient. Gram stain, colony characteristics, and conventional biochemical tests were used to classify the gram-negative bacteria at the species level. Antimicrobial susceptibility testing was carried out to screen beta-lactam and carbapenem drug-resistant bacteria. The E-test was conducted for extended-spectrum-beta-lactamase and AmpC-beta-lactamase-producers. A modified and EDTA-modified carbapenem inactivation method was conducted for carbapenemase and metallo-beta-lactamases producers. Data collected using structured questionnaires and medical records were reviewed, encoded, and cleaned using EpiData V3.1. software. The cleaned data were exported and analyzed using SPSS version 24 software. Descriptive statistics and multivariate logistic registration models were used to describe and assess factors associated with acquiring drug-resistant bacteria infection. A p-value <0.05 was considered statistically significant.
      Result: Among 1486 samples, 231 gram-negative bacteria were identified; of these, 195(84.4%) produce drug-hydrolyzing enzymes, and 31(13.4%) produce more than one drug-hydrolyzing enzyme. We found 54.0% and 25.7% of the gram-negative bacteria to be extended-spectrum-beta-lactamase and carbapenemase-producing, respectively. The extended-spectrum-beta-lactamase plus AmpC-beta-lactamase-producing bacteria account for 6.9%. Among the different isolates Klebsiella pneumonia 83(36.7%) was the highest drug-hydrolyzing enzyme-producing bacteria. Acinetobacter spp 25(53.2%) was the most carbapenemase producer. Extended-spectrum-beta-lactamase and carbapenemase-producing bacteria were high in this study. A significant association between age groups and extended-spectrum-beta-lactamase producer bacterial infection was seen, with a high prevalence in neonates (p = <0.001). Carbapenemase showed a significant association with patients admitted to the intensive care unit (p = 0.008), general surgery (p = 0.001), and surgical intensive care unit (p = 0.007) departments. Delivery of neonates by caesarean section, and insertion of medical instruments into the body were exposing factors for carbapenem-resistant bacterial infection. Chronic illnesses were associated with an extended-spectrum-beta-lactamase-producing bacterial infection. Klebsiella pneumonia and Acinetobacter species showed the greatest rates of extensively drug-resistant (37.3%) and pan-drug-resistance (76.5%), respectively. According to the results of this study, the pan-drug-resistance prevalence was found to be alarming.
      Conclusion: Gram-negative bacteria were the main pathogens responsible for drug-resistant bloodstream infections. A high percentage of extended-spectrum-beta-lactamase and carbapenemase-producer bacteria were found in this study. Neonates were more susceptible to extended-spectrum-beta-lactamase and AmpC-beta-lactamase-producer bacteria. Patients in general surgery, caesarean section delivery, and intensive care unit were more susceptible to carbapenemase-producer bacteria. The suction machines, intravenous lines, and drainage tubes play an important role in the transmission of carbapenemase and metallo-beta-lactamase-producing bacteria. The hospital management and other stakeholders should work on infection prevention protocol implementation. Moreover, special attention should be given to all types of Klebsiella pneumoniae and pan-drug resistance Acinetobacter spp transmission dynamics, drug resistance genes, and virulence factors.
      Competing Interests: The authors have declared that no competing interests exist.
      (Copyright: © 2023 Beshah et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
    • References:
      Clin Infect Dis. 2009 Dec 15;49(12):1821-7. (PMID: 19911973)
      Am J Infect Control. 2022 Jun;50(6):673-679. (PMID: 34756966)
      J Clin Microbiol. 2013 Dec;51(12):4150-5. (PMID: 24108609)
      PLoS One. 2016 Apr 22;11(4):e0154092. (PMID: 27104910)
      Life (Basel). 2021 Jun 18;11(6):. (PMID: 34207043)
      Infect Drug Resist. 2022 Aug 31;15:5043-5059. (PMID: 36068835)
      Intensive Care Med. 2003 Apr;29(4):530-8. (PMID: 12664219)
      Ther Adv Infect Dis. 2018 Jan;5(1):11-18. (PMID: 29344356)
      J Trop Med. 2019 Sep 19;2019:6750864. (PMID: 31641359)
      J Antimicrob Chemother. 2020 Feb 1;75(2):271-282. (PMID: 31586417)
      PLoS One. 2019 Feb 11;14(2):e0212131. (PMID: 30742669)
      Mayo Clin Proc. 2015 Mar;90(3):395-403. (PMID: 25744116)
      Antimicrob Resist Infect Control. 2019 May 28;8:86. (PMID: 31161033)
      PLoS One. 2019 Sep 25;14(9):e0222911. (PMID: 31553773)
      Clin Infect Dis. 2004 Sep 15;39(6):812-8. (PMID: 15472813)
      Infect Drug Resist. 2019 Dec 20;12:3903-3910. (PMID: 31908502)
      PLoS One. 2015 Dec 15;10(12):e0144944. (PMID: 26670718)
      J Med Assoc Thai. 2014 Mar;97 Suppl 3:S35-45. (PMID: 24772579)
      BMC Res Notes. 2013 Jul 22;6:283. (PMID: 23875886)
      Crit Care. 2011;15(2):R100. (PMID: 21418635)
      PLoS One. 2020 Nov 12;15(11):e0241984. (PMID: 33180785)
      Antimicrob Resist Infect Control. 2017 Jan 5;6:2. (PMID: 28070309)
      Springerplus. 2015 Jul 03;4:314. (PMID: 26155453)
      Infect Drug Resist. 2017 Jan 25;10:27-34. (PMID: 28182124)
      Clin Microbiol Infect. 2012 Mar;18(3):268-81. (PMID: 21793988)
      Int J Biol Med Res. 2015 Nov;6(1):4709-4717. (PMID: 26997847)
      Lancet Infect Dis. 2018 Feb;18(2):e33-e44. (PMID: 29033034)
      Epidemiol Infect. 2019 Jan;147:e137. (PMID: 30869056)
      J Clin Microbiol. 2007 Mar;45(3):816-21. (PMID: 17166960)
      Future Microbiol. 2015;10(3):407-25. (PMID: 25812463)
      Int J Microbiol. 2020 Sep 10;2020:8853053. (PMID: 32963541)
      JAMA. 2013 Nov 27;310(20):2191-4. (PMID: 24141714)
      Matern Health Neonatol Perinatol. 2017 Jul 5;3:12. (PMID: 28690864)
      Clin Microbiol Rev. 2009 Jan;22(1):161-82, Table of Contents. (PMID: 19136439)
      BMC Infect Dis. 2014 Nov 28;14:489. (PMID: 25431091)
      Chest. 1992 Jun;101(6):1644-55. (PMID: 1303622)
      Ann Intensive Care. 2011 Nov 23;1:47. (PMID: 22112929)
      Saudi J Biol Sci. 2015 Jan;22(1):90-101. (PMID: 25561890)
      Curr Infect Dis Rep. 2018 Oct 10;20(12):48. (PMID: 30306354)
      Crit Care Med. 2020 Jul;48(7):939-945. (PMID: 32282351)
      Antimicrob Resist Infect Control. 2018 Nov 19;7:138. (PMID: 30479751)
    • الرقم المعرف:
      EC 3.5.2.6 (carbapenemase)
      0 (Anti-Bacterial Agents)
      EC 3.5.2.6 (beta-Lactamases)
      0 (Bacterial Proteins)
      0 (Carbapenems)
    • الموضوع:
      Date Created: 20230627 Date Completed: 20230629 Latest Revision: 20230701
    • الموضوع:
      20240829
    • الرقم المعرف:
      PMC10298750
    • الرقم المعرف:
      10.1371/journal.pone.0287453
    • الرقم المعرف:
      37368908